Fredun Pharma — 360° view

Fredun Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹268 crore and net profit of ₹19 crore for the September 2026 quarter.

Fredun Pharma (NSE: FREDUN) closed at ₹1,693.90 on 20 Nov 2026. Its market capitalisation is ₹2,901 crore and it trades at 54.2 times earnings.

Share price
₹1,693.90 (20 Nov 2026)
Market cap
₹2,901 Cr (20 Nov 2026)
P/E
54.18 (20 Nov 2026)
Revenue
₹268 Cr (September 2026 quarter)
Net profit
₹19 Cr (September 2026 quarter)
ROCE
21.5% (FY26)
ROE
15.8% (FY26)
Book value
₹196 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,735.00 / ₹1,195.20 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: FREDUN

Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.